✦ LIBER ✦

A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma

✍ Scribed by Jeffrey S. Weber; Wolfram E. Samlowski; Rene Gonzalez; Antoni Ribas; Joe Stephenson; Steven O'Day; Takami Sato; Robert Dorr; Kathryn Grenier; Evan Hersh

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 208 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25119

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined treatment with pegylated interf

Combined treatment with pegylated interferon–α-2a and dacarbazine in patients with advanced metastatic melanoma : A phase 2 study

✍ Axel Hauschild; Reinhard Dummer; Selma Ugurel; Katharina C. Kaehler; Friederike 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB

A phase II study of autologous irradiate

A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma

✍ J. Frederick Laucius; Audley J. Bodurtha; Michael J. Mastrangelo; Robert E. Bell 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 2 views

Eighteen patients with surgically incurable metastatic malignant melanoma were treated with a mixture of irradiated (15,000 rads) autologous tumors cells (1-2 X 10(8)) and BCG (Glaxo, 2-4.5 X 10(6) organisms), which was injected intradermally (in five divided doses) every 2 weeks (X5). Four of 18 (2

A Phase II study of “decrescendo” interl

A Phase II study of “decrescendo” interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy

✍ Omar Eton; Antonio C. Buzaid; Agop Y. Bedikian; Teresa M. Smith; Nicholas E. Pap 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

The authors tested a biotherapy regimen involving recombinant interferon-␣-2a (rIFN-␣-2a) and recombinant human interleukin-2 (rhIL-2), given in a "decrescendo" schedule over 5 days, for its activity and toxicity in 21 patients who previously had received chemotherapy for advanced melanoma. ## METH

A phase 2 study of tasisulam sodium (LY5

A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma

✍ John M. Kirkwood; Rene Gonzalez; Douglas Reintgen; Philip R. Clingan; Robert R. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB

A randomized phase 2 study of etaracizum

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

✍ Peter Hersey; Jeffrey Sosman; Steven O'Day; Jon Richards; Agop Bedikian; Rene Go 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

A phase III randomized trial of dacarbaz

A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma

✍ Sanjiv S. Agarwala; William Ferri; William Gooding; John M. Kirkwood 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## BACKGROUND. Metastatic melanoma is a disease associated with a poor prognosis, and dacarbazine is still the reference agent. The authors conducted a randomized trial to test the benefit of adding tamoxifen to dacarbazine and carboplatin chemotherapy for previously untreated patients with metast